7 Best Pharmaceutical Stocks to Buy for Income

[ad_1] The global pharmaceutical industry is expected to generate $1.15 trillion in sales in 2023, according to Statista. The oncology segment alone should see $188.2 billion in sales this year.…

A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

[ad_1] In pharma, you can take a larger slice of the healthcare pie than your peers, but you are still constrained by the size of the pie. No matter how…

Gilead cuts 7% of staff at Kite Pharma unit as ‘refreshed business strategy’ introduced

[ad_1] Gilead Sciences’ Kite Pharma cell therapy unit is undergoing a business review that will result in layoffs to about 7% of the organization’s workforce. In a letter sent to…

S&P 500, Nasdaq Extend Win Streaks

[ad_1] Major stock indexes ended mostly higher Wednesday, building on a long run of gains.  The S&P 500 added 0.1%, notching an eighth-straight session in the green. The Nasdaq Composite…

Blockbuster Cancer Treatment Stymied by Supply Chain—for Now

[ad_1] A cell therapy for multiple myeloma promises to be a major blockbuster for J&J and partner Legend, if they can increase manufacturing. [ad_2] Source link

Opinion | Gilead Sciences Is the Target of a Bizarre Legal Theory

[ad_1] A lawsuit claims the biotech innovator should have rolled out a new drug sooner. [ad_2] Source link

Higher Rates Are Coming for U.S. Companies

[ad_1] The burden of interest rates on most companies is still exceedingly low. But over the next year, that will start to change. [ad_2] Source link

Seagen’s Cancer Therapy Is Making It a Takeover Target

[ad_1] Health Novel cancer agents could shore up aging pharmaceutical portfolios for big drugmakers [ad_2] Source link

Companies Fight Back Against Premium Increases for Crucial Insurance

[ad_1] The prices for policies that cover directors and officers doubled for some businesses. [ad_2] Source link